PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

First vaccine for viral hepatitis C could become a reality

2011-04-02
(Press-News.org) Berlin, Germany, Friday 01 April 2011: Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.1,2

In the first study1, a therapeutic T-cell vaccine, based on novel adenoviral vectors was used on a small population of treatment naive patients with chronic genotype 1 HCV infection. Intra-muscular vaccination was administered 2 or 14 weeks into a 48-week course of treatment with Peg-IFNa2a/ribavirin. 50% of vaccinated patients had CD4+ and CD8+ HCV specific T-cell responses as detected by ELISpot at 2-8 weeks post boost, showing a strong immunogenicity for the vaccine. Local and systemic adverse events to vaccination were mild, with no evidence of liver immunopathology (measured by liver transaminase levels).

The second study2 looked at the potential for a prophylactic vaccine based on similar novel adenoviral vectors technology (replicative-defective human Ad6 and a novel simian AdCh3 vector that encode 1985 amino-acids derived from the NS3-5 region of a genotype-1b strain). 27 healthy volunteers were vaccinated following a double prime, heterologous boost strategy. The vaccine induced polyfunctional CD4+ and CD8+ T cells responses which were maintained up to 52 weeks post prime. Overall vaccination was very well tolerated with mild/moderate local and systemic reactions and no serious adverse advents.

Professor Heiner Wedemeyer, EASL's Secretary General commented: "Vaccines are an exciting area of research now with the potential to add to the range of treatments available for patients with chronic viral hepatitis. These are early data but results are very encouraging indeed and as experts, we look forward to more scientific evidence being made available to support this new technology as a future treatment option as well as potentially preventing infection."

Previous research and data presented at the International Liver Congress shows that vaccination with adenoviral vectors induced highly potent and durable T-cell responses in healthy human and that similar vectors may prevent chronic infection in animals.3 This is the first time the immunogenicity and safety of vaccination was tested on HCV patients and healthy subjects.

### Notes to Editors

About EASL EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

EASL's main focus on education and research is delivered through numerous events and initiatives, including: The International Liver CongressTM which is the main scientific and professional event in hepatology worldwide Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology Journal of Hepatology published monthly Participation in a number of policy initiatives at European level

About The International Liver CongressTM 2011 The International Liver Congress™ 2011, the 46th annual meeting of the European Association for the study of the Liver, is being held at the Internationales Congress Centrum, Berlin, Germany from March 30 – April 3, 2011. The congress annually attracts over 7,500 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.

References 1. Kelly C et al. A therapeutic vaccine for HCV based on novel, rare, adenoviral vectors. Abstract presented at the International Liver CongressTM 2011. http://www1.easl.eu/easl2011/program/Orals/329.htm

2. Barnes E. Phase I trials of a highly immunogenic and durable T-cell vaccine for Hepatitis C virus based on novel, rare, adenoviral vectors. Abstract presented at the International Liver CongressTM 2011. http://www1.easl.eu/easl2011/program/Posters/Abstract1018.htm

3. Folgori A et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nature Medicine - 12, 190 - 197 (2006)


ELSE PRESS RELEASES FROM THIS DATE:

The future looks bright for HCV patients who have failed to respond to current treatments

2011-04-02
Berlin, Germany, Friday 1st April 2011: Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.1,2,3,4,5 The treatments have been tested for efficacy and safety in combination with PegIFN-alpha and ribavirin in patients that have previously failed treatment (either non-responder or relapse). Following different treatment and dosing, all of the trials ...

Fratricide of HBV-specific CD8 T cells by NK cells mediated through the TRAIL pathway

2011-04-02
A new study presented today at the International Liver CongressTM shows a novel pathway where activated natural killer (NK) cells expressing death ligands may excessively down-modulate the antiviral immune response in chronic HBV patients.1 Blocking the TNF-related apoptosis-inducing ligand (TRAIL) pathway partially reconstitutes HBV-specific T cells, suggesting that these cells are vulnerable to NK cell-mediated apoptosis through this death ligand pathway. NK cells are one of the main effectors of the innate immune response that plays a key role in containing intracellular ...

777 Dragon Casino Pays Out 100.16% On Poker Games

777 Dragon Casino Pays Out 100.16% On Poker Games
2011-04-02
777 Dragon Casino, who assert that they are the best Asian online casino, have definitely stepped up to the plate with their latest Casino Payout Reports. With the latest payout report that has been released by the independent auditing body who regularly audits the casino, during the month of February, 2011, Poker Games have proven to be a prominent part of the casino's payouts as they paid out 100.16%! Jessica Drake, spokesperson and manager at the casino, explained, "Receiving our payout report on a monthly basis keeps us in the know about how well our players are ...

Cinema Casino Cracks 100% in Payouts on Table Games

Cinema Casino Cracks 100% in Payouts on Table Games
2011-04-02
Cinema Online Casino has just reported payouts of over 100% for Table Games during the month of February, 2011. Casino Table Games by definition include Blackjack, Poker, Craps, Baccarat and Roulette amongst other games. Victor Roberts, the representative for the casino, commented that Table Games seem to offer prominent payouts at the casino. "We have noticed a trend on Table Game Payouts over a period of time, and our Table Games definitely seem to be highly generous when it comes to our players and winners. We have had a run of great payouts for our players on Table ...

Win over $3,000,000 in Progressives at Casino Aus

2011-04-02
The prominent Australian Online Casino, Casino Aus has just announced that they have two major jackpots that are both ready to spill. The combined winnings from the two jackpots are sitting at over $3,000,000 "It is the first time in a long time that two of our most important progressives have matured simultaneously. Currently, they are growing fast and it is quite like a horse race to see which one will crack first. I think that this is going to be a photo finish. Currently, these jackpots are neck-in-neck, and standing on a combined value of over $3,000,000!" Conner ...

Over $3,000,000 in Progressives to be Won at Crazy Vegas Casino

Over $3,000,000 in Progressives to be Won at Crazy Vegas Casino
2011-04-02
At Crazy Vegas Online Casino, 2 massive jackpots are ready to spill out over 3 Million in grand prizes. The two jackpots combined are offering a massive jackpot prize for the lucky winners who will crack these progressive games shortly. King Cashalot is a 5-Reel, 9-Payline Medieval-themed Video Slot Progressive Jackpot offering a Bonus Game, Multiplying Wilds and Scatters, and the Progressive Bonus Feature, which is currently sitting at an immense $1,420,000. Mega Moolah Progressive is about to crack $1.6 Million as it is sitting at $1,594,000! Themed around African ...

Got a craving for fast food? Skip the coffee, study says

2011-04-02
Eating a fatty fast food meal is never good for you, but washing that meal down with a coffee is even worse, according to a new University of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not only that a healthy person's blood sugar levels spike after eating a high-fat meal, but that the spike doubles after having both a fatty meal and caffeinated coffee – jumping to levels similar to those of people at risk for diabetes. "The results tell us that saturated fat interferes with the body's ability to clear sugars from the blood and, when combined with ...

Could maple syrup from Canada be the next champion food?

2011-04-02
Contact: Cassandra Bianco cbianco@crt-tanaka.com 646-218-6009 Federation of Quebec Maple Syrup Producers Could maple syrup from Canada be the next champion food? Maple syrup may pack similar health benefits to those found in berries, tea, red wine and flax seed New York – April 1, 2011 - There's more good news about pure maple syrup from the University of Rhode Island (URI). Researchers there have now identified 54 compounds in maple syrup from Canada, double the amount previously reported, and many with antioxidant activity and potential health benefits. In laboratory ...

New lung cancer staging system (TNM 7) better predicts local/regional recurrence, study shows

2011-04-02
The new TNM 7 lung cancer staging system seems to be a better predictor of local or regional recurrence of lung cancer following surgery, according to a study published in the April issue of the Journal of Thoracic Oncology. Being able to better define which patients might experience a cancer recurrence is important, especially given the controversies surrounding the use of adjuvant therapies, particularly postoperative radiation therapy (RT), for patients with non-small cell lung cancer (NSCLC). In 2009, the International Association for the Study of Lung Cancer (IASLC) ...

Soy increases radiation's ability to kill lung cancer cells, study shows

2011-04-02
A component in soybeans increases radiation's ability to kill lung cancer cells, according to a study published in the April issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer. "To improve radiotherapy for lung cancer cells, we are studying the potential of natural non-toxic components of soybeans, called soy isoflavones, to augment the effect of radiation against the tumor cells and at the same time protect normal lung against radiation injury," said Dr. Gilda Hillman, an associate professor ...

LAST 30 PRESS RELEASES:

New strategies to enhance chiral optical signals unveiled

Cambridge research uncovers powerful virtual reality treatment for speech anxiety

2025 Gut Microbiota for Health World Summit to spotlight groundbreaking research

International survey finds that support for climate interventions is tied to being hopeful and worried about climate change

Cambridge scientist launches free VR platform that eliminates the fear of public speaking

Open-Source AI matches top proprietary model in solving tough medical cases

Good fences make good neighbors (with carnivores)

NRG Oncology trial supports radiotherapy alone following radical hysterectomy should remain the standard of care for early-stage, intermediate-risk cervical cancer

Introducing our new cohort of AGA Future Leaders

Sharks are dying at alarming rates, mostly due to fishing. Retention bans may help

Engineering excellence: Engineers with ONR ties elected to renowned scientific academy

New CRISPR-based diagnostic test detects pathogens in blood without amplification

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Growing solar: Optimizing agrivoltaic systems for crops and clean energy

Scientists discover how to reactivate cancer’s molecular “kill switch”

YouTube influencers: gaming’s best friend or worst enemy?

uOttawa scientists use light to unlock secret of atoms

NJIT mathematician to help map Earth's last frontier with Navy grant

NASA atmospheric wave-studying mission releases data from first 3,000 orbits

‘Microlightning’ in water droplets may have sparked life on Earth

Smoke from wildland-urban interface fires more deadly than remote wildfires

What’s your body really worth? New AI model reveals your true biological age from 5 drops of blood

Protein accidentally lassos itself, helping explain unusual refolding behavior

With bird flu in raw milk, many in U.S. still do not know risks of consuming it

University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease

UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS

Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it

A closer look at biomolecular ‘silly putty’

Oxytocin system of breastfeeding affected in mothers with postnatal depression

Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles

[Press-News.org] First vaccine for viral hepatitis C could become a reality